Opinions
Darren Sissons
Novozymes A/S ADR
NVZMY-PK
BUY ON WEAKNESS
Jul 31, 2018
N/A
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
HOLD
BUY
Are merging with another Danish company which will remake the company because it gets them into the biologics industry. The street didn't like the price they were paying at first, but the deal offers growth. Shares have been growing and will continue to do. Their dividend growth averages 10%. He's adding shares.
0
This is an industrial enzymes company, spun out of Novo Nordisk. It has been a solid performer with a good balance sheet. The problem is that there are rarely good buying opportunities. It trades at a high earnings multiple and rarely misses earnings estimates, for example. This would be a good company to buy in a recession.